Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-22
    E.g., 2018-09-22

Articles

173342 items
9:32 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Gritstone amends IPO

Immuno-oncology company Gritstone Oncology Inc. (Emeryville, Calif.) amended on Sept. 17 its proposed IPO on NASDAQ and now plans to sell 6.1 million shares at $13-$15. At the midpoint, the company would raise $85 million...
9:32 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Equillium proposes $86.3M IPO

Autoimmune and inflammatory disease company Equillium Inc. (La Jolla, Calif.) proposed to raise up to $86.3 million on Sept. 17 in an IPO on NASDAQ underwritten by Jefferies, Leerink and Stifel. The company has U.S. and...
9:31 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Gene therapy company Horama closes series B at €22.5M

Horama S.A. (Paris, France) closed its series B round at €22.5 million ($26.3 million) with an additional €3.5 million ($4.1 million) investment from V-Bio Ventures. Last year, the company raised €19 million ($22.2 million) in...
9:31 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

WuXi AppTec queues up for Hong Kong listing

Less than five months after its IPO in Shanghai, WuXi AppTec Co. Ltd. (Shanghai:603259) proposed Sept. 18 to list on the Hong Kong stock exchange in an offering underwritten by Morgan Stanley Asia, Huatai Financial...
9:30 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Other Financial News

Versant seeking $500M for seventh fund

Versant Ventures is targeting $500 million for Versant Venture Capital VII, according to an SEC filing. The firm declined to comment on the new fund. Versant invests in biotechs in the U.S., Canada and Europe. The...
9:30 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

G1 prices $180M follow-on

G1 Therapeutics Inc. (NASDAQ:GTHX) raised $180 million in a follow-on that priced after hours on Sept. 18. G1 sold 3 million shares at $60 in an offering underwritten by J. P. Morgan, Cowen, Needham, Wedbush, BTIG...
9:30 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

argenx prices $300M follow-on

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) raised $300.6 million in a follow-on that priced after hours on Sept. 18. argenx sold 3.5 million ADSs at $86.50, an 8% discount to its NASDAQ close of $93.77 on Sept. 17,...
9:29 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Ahead of Phase III mucositis study, Galera raises $150M

Galera Therapeutics Inc. (Malvern, Pa.) raised a combined $150 million in a $70 million series C round and $80 million royalty deal led by new investor Clarus. The fund-raising comes ahead of Galera's planned Phase...
9:29 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Other News

Novo's R&D restructuring adds to innovation push

Four new R&D centers fueled by a dedicated business development unit and increased investment in machine learning and AI form the basis of an R&D restructuring announced by Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) on...
9:29 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Other News

Siga signs BARDA contract for smallpox drug worth up to $629M

Siga Technologies Inc. (NASDAQ:SIGA) signed a contract with HHS's Biomedical Advanced Research and Development Authority (BARDA) to deliver oral and IV formulations of its TPOXX tecovirimat drug to the U.S. Strategic National Stockpile. In July,...

Pages